Aortic Valve Calcification, Aortic Valve Disease, Aortic Valve Stenosis
Conditions
Brief summary
The objective of this study is to evaluate the safety and effectiveness of the MicroPort's Valve and delivery system for transcatheter aortic valve implantation (TAVI) in severe aortic stenosis who are considered unsuitable for Surgical Valve Replacement.
Detailed description
1. Evaluate the performance, safety and clinical benefit of MicroPort's aortic valve prosthesis and delivery system in intervention by peripheral artery. 2. The study Continuous observe 12 months of safety and efficacy. Approximately 89 patients are recruited in the study with native aortic valve stenosis which are considered unsuitable for Surgical Valve Replacement.
Interventions
DEVICEMicroPort's Transcatheter Aortic Valve and Delivery System
Sponsors
Shanghai MicroPort Medical (Group) Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 18 years or older, male or non pregnant women; * Senile degenerative aortic valve stenosis with echocardiography derived criteria: mean gradient ≥ 40 mmHg, or jet velocity ≥ 4.0 m/s, or an aortic valve area (AVA) of \< 1.0 cm2 (or AVA index \< 0.6 cm2/m2) * Symptomatic due to aortic valve stenosis as demonstrated by NYHA (New York Heart Association) Functional Class ≥ II * Expectation of life\>12 months * Calcific aortic stenosis, which is suitable for transcatheter aortic valve implantation anatomically * is evaluated by at least two cardiovascular physicians, and they agreed that medical factors precluding operation suitable for surgery (the probability of death or serious, irreversible morbidity exceeded 50%) * The subject agreed to comply follow-up evaluation
Exclusion criteria
* Evidence of an acute myocardial infarction ≤ 1 month before the intended treatment * aortic valve is a congenital unicuspid valve, or is non-calcified. * Any therapeutic invasive cardiac procedure resulting in a permanent implant that is performed within 30 days * Implanted any heart valve prosthesis, prosthetic valve ring, severe（\>3＋）mitral valve insufficiency * Blood dyscrasia such as leukopenia (WBC \< 3×109/L), acute anemia (Hgb \< 90 g/L), thrombocytopenia (PLT \< 50×109/L), bleeding diathesis, or history of coagulopathy. * Untreated clinically significant coronary artery disease requiring revascularization * Hemodynamic instability requiring mechanical cardiac assist or mechanical hemodynamic support devices * Need for emergency surgery for any reason * Hypertrophic cardiomyopathy with or without obstruction * Severe ventricular dysfunction with LVEF (Left ventricular ejection fraction) \< 20% * Echocardiographic evidence of intracardiac mass, thrombus or vegetation * Active peptic ulcer or upper gastro-intestinal bleeding within the prior 3 months * A known hypersensitivity or contraindication to aspirin, heparin, ticlopidine, clopidogrel, Nitinol, or sensitivity to contrast media which cannot be adequately pre-medicated. * Native aortic annulus size \< 17 mm or\> 29 mm. * Patient refuses aortic valve replacement surgery. * Cerebrovascular Accident (CVA) within 6 months, including TIA (transient ischemic attack). * Renal insufficiency (creatinine \> 3.0 mg/dL) and/or end stage renal disease requiring chronic dialysis. * Life expectancy \< 12 months * Significant abdominal or thoracic aorta disease, including aneurysm, marked tortuosity (hyperacute bend), aortic arch atheroma, narrowing of the abdominal aorta (especially with calcification and surface irregularities), or severe unfolding and tortuosity of the thoracic aorta * Iliofemoral vessel characteristics that would preclude safe placement of 16F to 19F introducer sheath such as severe obstructive calcification, severe tortuosity * Active bacterial endocarditis or other active infections. * Bulky calcified aortic valve leaflets in close proximity to coronary ostia * severe incapacitating dementia. * Currently participating in an investigational drug or another device study that has not reached its primary endpoint. * Researchers identify that the patients with poor compliance who cannot be completed in accordance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| All cause mortality or major stroke at 12 months. | 12 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| MACCE(major adverse cardiovascular and cerebrovascular events) | 30 days, 3, 6 and 12 months | MACCE is defined as a composite of: * Myocardial infarction (MI) * Hemorrhage * renal failure * vascular complications * block * ventricular arrhythmias |
| Device success | 7 days post-operation | Device success is defined as * The device successfully enter the vascular approach, transport and release * The valve is placed in the correct anatomical position * The valve achieve the expected effect (mean aortic pressure \< 20mmHg or peak velocity \< 3m/s, with no severe aortic regurgitation or paravalvular leakage) |
| Valve performance | 30 days, 3, 6 and 12 months | Valve performance means: * Transvalvular mean gradient * Effective orifice area * Degree of aortic valve regurgitation (transvalvular and paravalvular) |
| The improvement of heart function | 30 days, 3, 6 and 12 months | — |
Countries
China
Contacts
Primary ContactDavid Liu, Medical Doctor
Outcome results
None listed